Correlation analysis of survival time in patients with advanced breast cancer and the scores of Care Evaluation Scale in cancer patients
10.3760/cma.j.cn115682-20220318-01285
- VernacularTitle:乳腺癌晚期患者生存时间与癌症患者照护评估量表评分的相关性分析
- Author:
Jiumei LIU
1
;
Yanjie SONG
;
Lin SHEN
;
Chunping XIAO
Author Information
1. 青岛大学附属青岛市中心医院乳腺外一、三科，青岛 266042
- Keywords:
Breast neoplasms;
Advanced breast cancer;
Care Evaluation Scale in cancer patients;
Survival time;
Estimation
- From:
Chinese Journal of Modern Nursing
2022;28(28):3924-3929
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the value of Care Evaluation Scale (CES) in cancer patients for predicting survival time in patients with advanced breast cancer.Methods:From November 2018 to June 2020, the convenient sampling was used to select 140 patients with advanced breast cancer who were treated in Qingdao Central Hospital Affiliated to Qingdao University and 140 home caregivers as the research objects. Researchers contacted home caregivers of patients with advanced breast cancer to set up a time and place to conduct one-on-one surveys of research objects using the Cancer Patient CES. Pearson correlation was used to analyze the correlation between survival time and CES score in patients with advanced breast cancer. Multiple stepwise regression analysis was used to analyze the influencing factors of CES scores in patients with advanced breast cancer. A total of 140 questionnaires were distributed, of which 133 were valid, and the effective recovery rate was 95.00% (133/140) .Results:Among the 133 patients with advanced breast cancer, 76 were Luminal A, 19 were Luminal B, 12 were ERBB 2+ and 26 were Basal-like. Luminal type A advanced breast cancer patients had the longest survival time, and the differences were statistically significant compared with those of ERBB 2+ and Basal-like advanced breast cancer patients ( P<0.05) . There was no statistically significant difference in survival time between Luminal B type advanced breast cancer and Luminal A, ERBB 2+ and Basal-like advanced breast cancer patients ( P>0.05) . Luminal type A advanced breast cancer patients had the highest CES score, and the differences were statistically significant compared with those of Luminal type B, ERBB 2+ and Basal-like advanced breast cancer patients ( P<0.05) . There was no statistically significant difference in the CES score between Luminal B advanced breast cancer and Luminal A, ERBB 2+ and Basal-like advanced breast cancer ( P>0.05) . Pearson correlation analysis found that the survival time of patients with advanced breast cancer was positively correlated with the CES score ( r=0.892, P<0.05) . The influencing factors of CES empowerment in patients with advanced breast cancer included physical care provided by doctors, mental health care, environment, explanation or instructions by doctors to family members, collaboration and persistence, consideration for family members, availability, cost, explanation or instructions by doctors to patients and physical care provided by nurses. Conclusions:CES in cancer patients can effectively predict the survival time of patients with advanced breast cancer. The molecular types of patients with advanced breast cancer are different and the effect of predicting survival time is also different.
